{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:37:16Z","timestamp":1791585436288,"version":"4.3.4"},"reference-count":75,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin\u2019s lymphoma in adults. Despite the recognition of transcriptional subtypes with distinct functional characteristics, patient outcomes have not been substantially altered since the advent of chemoimmunotherapy (CIT) twenty years ago. Recently, a few pivotal studies added to the disease heterogeneity by describing several activating mutations, which have been associated with disease presentation, B-cell function and behavior, and final outcome. DLBCL arises from antigen exposed B-cells, with the B-cell receptor (BCR) playing a central role. BCR-activity related mutations, such as CD79B and MYD88, are responsible for chronic activation of the BCR in a substantial subset of patients. These mutations, often coexisting in the same patient, have been found in a substantial subset of patients with immune-privileged (IP) sites DLBCLs, and are drivers of lymphoma development conferring tissue-specific homing properties. Both mutations have been associated with disease behavior, including tumor response either to CIT or to BCR-targeted therapy. The recognition of CD79B and MYD88 mutations will contribute to the heterogeneity of the disease, both in recognizing the BCR as a potential therapeutic target and in providing genetic tools for personalized treatment.<\/jats:p>","DOI":"10.3390\/cancers12102913","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T21:42:21Z","timestamp":1602798141000},"page":"2913","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0883","authenticated-orcid":false,"given":"Carlo","family":"Visco","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Hematology, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8177-374X","authenticated-orcid":false,"given":"Ilaria","family":"Tanasi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4347-3775","authenticated-orcid":false,"given":"Francesca Maria","family":"Quaglia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Ferrarini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Fraenza","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-2040","authenticated-orcid":false,"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1056\/NEJMc0902616","article-title":"Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma","volume":"360","author":"Alizadeh","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive Lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic Active B Cell Receptor Signaling in Diffuse Large B Cell Lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-\u03baB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.semcancer.2013.09.004","article-title":"Marginal zone lymphomas and infectious agents","volume":"23","author":"Ferreri","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20062041","article-title":"Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma","volume":"204","author":"Lenz","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1084\/jem.20061923","article-title":"Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors","volume":"204","author":"Horikawa","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101","volume":"41","author":"Gauld","year":"2004","journal-title":"Mol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/intimm\/10.3.285","article-title":"Receptor-specific induction of NF-\u03baB components in primary B cells","volume":"10","author":"Francis","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood.V99.6.1913","article-title":"BCR ligation reprograms B cells for migration to the T zone and B-cell follicle sequentially","volume":"99","author":"Verschelde","year":"2002","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35123","DOI":"10.18632\/oncotarget.26212","article-title":"CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton\u2019s tyrosine kinase","volume":"9","author":"Montresor","year":"2018","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.4049\/jimmunol.153.5.1990","article-title":"Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen","volume":"153","author":"Lenschow","year":"1994","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.it.2017.06.010","article-title":"Tonic Signals: Why Do Lymphocytes Bother?","volume":"38","author":"Myers","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12792","article-title":"Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment","volume":"291","author":"Young","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00129039-200106000-00001","article-title":"CD79: A review","volume":"9","author":"Chu","year":"2001","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1038\/sj.onc.1208075","article-title":"Src-family kinases in B-cell development and signaling","volume":"23","author":"Gauld","year":"2004","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3324\/haematol.2019.227272","article-title":"MYD88 in the driver\u2019s seat of B-cell lymphomagenesis: From molecular mechanisms to clinical implications","volume":"104","author":"Schrader","year":"2019","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20131424","article-title":"Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance","volume":"211","author":"Wang","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2015-11-684183","article-title":"B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice","volume":"127","author":"Knittel","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0130-3","article-title":"Loss of TNFAIP3 enhances MYD88 L265P -driven signaling in non-Hodgkin lymphoma","volume":"8","author":"Wenzl","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","author":"Kraan","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10165","DOI":"10.2147\/OTT.S222189","article-title":"Prevalence And Clinical Significance Of Oncogenic CD79B And MYD88 Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China","volume":"12","author":"Chen","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1038\/s41375-019-0509-6","article-title":"Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes","volume":"33","author":"Alkodsi","year":"2019","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3324\/haematol.2018.214122","article-title":"MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis","volume":"105","author":"Vermaat","year":"2020","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/leu.2014.184","article-title":"MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma","volume":"28","author":"Bellosillo","year":"2014","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-15-1525","article-title":"MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome","volume":"22","author":"Rovira","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41598-017-01998-5","article-title":"Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: A meta-analysis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","article-title":"High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma","volume":"131","author":"Schrader","year":"2018","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/modpathol.2013.156","article-title":"Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma","volume":"27","author":"Andrique","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PAS.0000000000000592","article-title":"Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma","volume":"40","author":"Taniguchi","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00277-017-3094-7","article-title":"Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations","volume":"96","author":"Cao","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood.V126.23.3881.3881","article-title":"Clinical Significance of MYD88 Mutation in Patients with Diffuse Large Cell Lymphoma","volume":"126","author":"Seki","year":"2015","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood.2019000022","article-title":"Single-cell MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis","volume":"134","author":"Tan","year":"2019","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.humpath.2013.10.023","article-title":"CD79B and MYD88 mutations in diffuse large B-cell lymphoma","volume":"45","author":"Kim","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ejh.13191","article-title":"CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential","volume":"102","author":"Yonese","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","article-title":"Extranodal Diffuse Large B-Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence","volume":"19","author":"Ollila","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3892\/mmr.2020.11186","article-title":"Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR","volume":"22","author":"Niu","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Bedsaul, J.R., Carter, N.M., Deibel, K.E., Hutcherson, S.M., Jones, T.A., Wang, Z., Yang, C., Yang, Y.-K., and Pomerantz, J.L. (2018). Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease. Front. Immunol, 9.","DOI":"10.3389\/fimmu.2018.02105"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.3324\/haematol.2016.161893","article-title":"Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79","volume":"102","author":"Deng","year":"2017","journal-title":"Haematologica"},{"key":"ref_66","unstructured":"(2020, June 13). Clinical Trial: NCT02252146\u2014My Cancer Genome. Available online: https:\/\/www.mycancergenome.org\/content\/clinical_trials\/NCT02252146\/."},{"key":"ref_67","unstructured":"Idera Pharmaceuticals Inc (2020, June 13). An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients with Relapsed or Refractory Waldenstr\u00f6m\u2019s Macroglobulinemia Who Completed Study 8400-401, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.23620","article-title":"Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia","volume":"89","author":"Ghobrial","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Ramchandren","year":"2019","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"He, Y., Li, J., Ding, N., Wang, X., Deng, L., Xie, Y., Ying, Z., Liu, W., Ping, L., and Zhang, C. (2019). Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma. J. Exp. Clin. Cancer Res., 38.","DOI":"10.1186\/s13046-019-1076-4"},{"key":"ref_71","unstructured":"Denovo Biopharma LLC (2020, June 13). A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1TM, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Watanabe, J., Natsumeda, M., Okada, M., Kobayashi, D., Kanemaru, Y., Tsukamoto, Y., Oishi, M., Kakita, A., and Fujii, Y. (2019). High Detection Rate of MYD88 Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas. JCO Precis. Oncol., 1\u201313.","DOI":"10.1200\/PO.18.00308"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/hon.2489","article-title":"The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid","volume":"36","author":"Minnema","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Bohers, E., Viailly, P.-J., Becker, S., Marchand, V., Ruminy, P., Maingonnat, C., Bertrand, P., Etancelin, P., Picquenot, J.-M., and Camus, V. (2018). Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: Analysis of a prospective cohort. Blood Cancer J., 8.","DOI":"10.1038\/s41408-018-0111-6"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements as Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"JCO"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2913\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:19:12Z","timestamp":1760177952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":75,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cancers12102913"],"URL":"https:\/\/doi.org\/10.3390\/cancers12102913","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]}}}